Longeveron shares plunge after Phase 2b stem-cell trial misses endpoint
Longeveron said its Phase 2b trial of a stem-cell therapy for a pediatric heart condition failed to meet its primary endpoint, sending shares down about 60% to $2.65 in after-hours trading.